Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene

Transplantation

Volumn 69, Issue 10, 2000, Pages 2154-2161

  Thomas Vaslin, Véronique ^a   Bellier, Bertrand ^a   Cohen, José L ^b   Boyer, Olivier ^a   Raynal Raschilas, Nathalie ^c   Glotz, Denis ^c   Klatzmann, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Génopoïétic   (France)

^c HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; IMMUNOCOMPETENCE; LYMPHOCYTE DEPLETION; LYMPHOCYTOTOXICITY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TRANSPLANTATION; SUICIDE GENE; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0034720613     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005270-00034     Document Type: Article

References (46)

1. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961.
2. Wood KJ. Induction of tolerance to cardiac allografts. Curr Opin Cardiol 1996; 11: 208.
3. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism [see comments]. Nature (Lond) 1999; 397: 530.
4. Rossini AA, Greiner DL, Mordes JP. Induction of immunologic tolerance for transplantation. Physiol Rev 1999; 79: 99.
5. Wood K. Gene therapy and allotranplantation. Curr Opin Immunol 1996; 9: 662.
6. Gianello P. [Is there a place for gene therapy in organ transplantation?]. Ann Chir 1997; 51: 593.
7. Heyman RA, Borrelli E, Lesley J, et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci USA 1989; 86: 2698.
8. Kamogawa Y, Minasi L, Carding S, Bottomly K, Plavell R. The relationship of IL-4 and IFN gamma-producing T cells studied by lineage ablation of IL-4 producing cells. Cell 1993; 75: 985.
9. Minasi L, Kamogawa Y, Carding S, Bottomly K, Flavell R. The selective ablation of interleukin 2-producing cells isolated from transgenic mice. J Exp Med 1993; 177: 1451.
10. Dziezark E, Daly B, Fraser P, Larsson L, Muller A. Thy-1 tk transgenic mice with a conditional lymphocyte deficiency. Int Immunol 1993; 5: 975.
11. Salomon B, Lores P, Pioche C, Racz P, Jami J, Klatzmann D. Conditional ablation of dendritic cells in transgenic mice. J Immunol 1994; 152: 537.
12. Anonymous. Human gene marker/therapy clinical protocols. Hum Gene Ther 1996; 7: 2287.
13. Cohen JL, Boyer O, Thomas-Vaslin V, Klatzmann D. Suicide gene-mediated modulation of graft-versus-host disease. Leuk Lymphoma 1999; 34: 473.
14. Cohen J, Boyer O, Salomon B, et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T-lymphocytes. Blood 1997; 89: 4636.
15. Helene M, Lake-Bullock V, Bryson JS, Jennings CD, Kaplan AM. Inhibition of graft-versus-host disease: use of a T cell-controlled suicide gene. J Immunol 1997; 158: 5079.
16. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science 1997; 276: 1719.
17. Cohen JL, Boyer O, Klatzmann D. Would suicide gene therapy solve the T-cell dilemma of allogeneic bone marrow transplantation? Immunol Today 1999; 20: 172.
18. Salmon P, Boyer O, Lores P, Jami J, Klatzmann D. Characterization of an intronless CD4 minigene expressed in mature CD4 and CD8 T cells, but not expressed in immature thymocytes. J Immunol 1996; 156: 1873.
19. Cohen JL, Boyer O, Salomon B, et al. Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase delta TK gene. Transgenic Res 1998; 7: 321.
20. Salmon P, Giovane A, Wasylyk B, Klatzmann D. Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promoter is tissue-specific and is activated by Ets proteins. Proc Natl Acad Sci USA 1993; 90: 7739.
21. Sawada S, Littman DR. Identification and characterization of a T-cell-specific enhancer adjacent to the murine CD4 gene. Mol Cell Biol 1991; 11: 5506.
22. 22: Sawada S, Scarborough JD, Killeen N, Littman DR. A lineage-specific transcriptional silencer regulates CD4 gene expression during T lymphocyte development. Cell 1994; 77: 917.
23. + T cells. J Immunol 1997; 159: 3383.
24. Thomas-Vaslin V, Salaün J, Gajdos B, Le Douarin N, Coutinho A, Bandeira A. Thymic epithelium induces full tolerance to skin and heart but not to B lymphocyte grafts. Eur J Immunol 1995; 25: 438.
25. Rocha B, Freitas AA, Coutinho A. Population dynamics of T lymphocytes: renewal rate and expansion in the peripheral lymphoid organs. J Immunol 1983; 131: 2158.
26. Modigliani Y, Thomas-Vaslin V, Bandeira A, et al. Lymphocytes selected in allogeneic thymic epithelium mediate dominant tolerance towards tissue graft of the thymic epithelium haplotype. Proc Natl Acad Sci USA 1995; 92: 7555.
27. Morita H, Sugiura K, Inaba M, et al. A strategy for organ allografts without using immunosuppressants or irradiation. Proc Natl Acad Sci USA 1998; 95: 6947.
28. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (Lond) 1996; 381: 434.
29. Shizuru JA, Alters SE, Fathman CG. Anti-CD4 monoclonal antibodies in therapy: creation of nonclassical tolerance in the adult. Immunol Rev 1992; 129: 105.
30. Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 1996; 157: 1944.
31. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998; 16: 619.
32. O Manilay J, Sykes M. Natural killer cells and their role in graft rejection. Curr Opin Immunol 1998; 10: 532.
33. Johnson LL. At how many histocompatibility loci do congenic mouse strains differ? Probability estimates and some implications. J Hered 1981; 72: 27.
34. Peugh WN, Superina RA, Wood KJ, Morris PJ. The role of H-2 and non-H-2 antigens and genes in the rejection of murine cardiac allografts. Immunogenetics 1986; 23: 30.
35. Vriens PW, Nisco SJ, Hoyt EG, et al. Tissue-specific differences in the establishment of tolerance: tolerogenic effects of lung allografts in rats. Transplantation 1994; 57: 1795.
36. Nicolls M, Aversa G, Pearce N, et al. Induction of long term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993; 55: 459.
37. + T cells. J Exp Med 1993; 177: 35.
38. Matsuura T, Imanishi M, Hara Y, et al. Suppressed alloreactivity and mixed chimerism in rats with accepted cardiac allografts by intrathymic injection of donor bone marrow cells. Transpl Int 1997; 10: 262.
39. Eichwald EJ, Shelby J. Serum and cell-mediated responses in tolerance and hyperacute rejection of transplanted mouse hearts. Transplantation 1987; 43: 520.
40. Larsen CP, Barker H, Morris PJ, Austyn JM. Failure of mature dendritic cells of the host to migrate from the blood into cardiac or skin allografts. Transplantation 1990; 50: 294.
41. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens: a novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
42. de Waal LP, van Twuyver E. Blood transfusion and allograft survival: is mixed chimerism the solution for tolerance induction in clinical transplantation? Crit Rev Immunol 1991; 10: 417.
43. Hall BM, Dorsch SE. Cells mediating allograft rejection. Immunol Rev 1984; 77: 31.
44. Hamano K, Rawsthorne MA, Bushell AR, Morris PJ, Wood KJ. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Transplantation 1996; 62: 856.
45. EhI S, Aichele P, Ramseier H, et al. Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Nat Med 1998; 4: 1015.
46. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993; 259: 974.